Discussing Biogen's Regulatory Chances for Aducanumab in Alzheimer's with an Alzheimer's Expert.Ticker(s): BIIB
Name: Dr Russell Swerdlow - MD
Institution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease and very familiar with the Aducanumab public literature.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
Questions to come from STAT Reporters!Added By: joe_mccann
Is there any new information on when the FDA will finalize their decision on the aducanumab review ?
Considering the new data provided by Biogen, which could be the arguments for the FDA to reject aducanumab ? How strong is this data ?Added By: userccea4246
Given the very limited availability of PET scanners around the world, how feasible will any anti-Amyloid treatment be for the general public?
So if this data set is similar to others we've seen before in terms of issues with interpreting the data, why go ahead now with an application? What is the difference in this case or in Biogen's estimation?Added By: katy riddick
Instead of building a new global infrastructure in years or decades, how much faster could patients be served if there were a new noninvasive test that doesn't require spinal tap or blood draw?
How do you think patients will be diagnosed if aducanumab is approved? Not enough neurologists, cost of diagnosis and monitoring for ARIA will all affect the real-world experienceAdded By: userb14365a2
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.